当前位置: 首页 >> 检索结果
1. Ultrasonography for the assessment of enthesitis in psoriatic arthritis: systematic review with meta-analysis.
作者: Noémie Bibas.;Caroline Pignon.;Clementina Lopez-Medina.;Frédérique Gandjbakhch.;Bruno Fautrel.;Laure Gossec.
来源: Rheumatology (Oxford). 2025年64卷5期2377-2384页
The specificity of US for enthesitis in PsA is unclear. The objective was to analyse the specificity of US enthesitis in Mode B and using power Doppler for the diagnosis of PsA through a systematic review with meta-analysis.
2. Risk factors of COVID-19 related hospitalization of paediatric patients with rheumatic diseases: a systematic review and meta-analysis.
作者: Qianzi Zhao.;Beth Wallace.;Tova Ronis.;Lawrence Jung.
来源: Rheumatology (Oxford). 2025年64卷5期2369-2376页
Among adults who develop coronavirus disease 2019 (COVID-19), those with rheumatic diseases (RDs) have similar hospitalization rates compared with those without RDs. Similar comparisons are lacking in children, due to the overall rarity of COVID-19-related hospitalization in this population. We aimed to examine the risk factors for COVID-19-related hospitalization in paediatric patients with RDs.
3. Association between antiphospholipid antibodies and diffuse alveolar haemorrhage risk in systemic lupus erythematosus: a systematic review and meta-analysis.
作者: Mariana González-Treviño.;Gabriel Figueroa-Parra.;Jeffrey X Yang.;Larry J Prokop.;Sherif M Gamal.;Mercedes A García.;Judith A James.;Jason S Knight.;M Hassan Murad.;Javier Narvaez.;Bernardo A Pons-Estel.;Rosana M Quintana.;Ulrich Specks.;Xuwei Yang.;Alí Duarte-García.
来源: Rheumatology (Oxford). 2025年64卷4期1598-1608页
To assess the association of aPL and diffuse alveolar haemorrhage (DAH) in patients with SLE by performing a systematic review and meta-analysis.
4. Impact of treatments on fatigue in axial spondyloarthritis: a systematic review and meta-analysis.
作者: Clémentine Delcourt.;Olivier Fakih.;Clément Prati.;Mickaël Chouk.;Daniel Wendling.;Frank Verhoeven.
来源: Rheumatology (Oxford). 2025年64卷4期1585-1597页
Fatigue is frequent in axial SpA (axSpA) and is difficult to improve. This systematic review aimed to assess the effects of axSpA treatment on fatigue.
5. Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis.
作者: Merlijn Wind.;Juan J Fierro.;Kitty W M Bloemenkamp.;Karina de Leeuw.;A Titia Lely.;Maarten Limper.;Marieke Sueters.;Y K Onno Teng.;Isabel J Walter.;Judith Kooiman.
来源: Lancet Rheumatol. 2024年6卷10期e667-e683页
To enhance patient-tailored preconception risk assessment for women with systemic lupus erythematosus (SLE), knowledge on risk factors associated with adverse pregnancy outcomes is required. Therefore, we did a systematic review and meta-analysis to identify and provide unambiguous effect sizes of preconception predictors of pregnancy outcomes in women with SLE.
6. Hepatitis B reactivation in PsA patients: an SLR and meta-analysis for IL-17, IL-23 and JAK inhibitors.
作者: Theodoros Androutsakos.;Konstantinos Dimitriadis.;Maria-Loukia Koutsompina.;Konstantinos D Vassilakis.;Avraam Pouliakis.;George E Fragoulis.
来源: Rheumatology (Oxford). 2025年64卷3期935-942页
HBV reactivation (HBVr) constitutes a side effect of the treatment of autoimmune rheumatic diseases. Even though HBVr risk of conventional synthetic DMARDs (csDMARDs) and anti-tumor necrosis factor (anti-TNF) agents has long been established, the risk of targeted synthetic (ts)DMARDs and anti-interleukin (anti-IL) agents remains largely unknown.
7. Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review.
作者: Koushan Kouranloo.;Mrinalini Dey.;Helen Elwell.;Veronica Yioe.;Lisa G Spencer.;Caroline V Cotton.
来源: Rheumatology (Oxford). 2025年64卷1期45-55页
Anti-synthetase syndrome (ASS) is a chronic autoimmune condition, with interstitial lung disease (ILD) being a key feature. This systematic literature review (SLR; CRD42023416414) aimed to summarize treatments and outcomes of ILD associated with ASS (ASS-ILD).
8. Association of ankylosing spondylitis with the risk of cancer: a meta-analysis of cohort studies.
作者: Lulin Yu.;Yici Yan.;Wenjing Liu.;Siyu Huang.;Leitao Sun.;Shanming Ruan.
来源: Rheumatology (Oxford). 2025年64卷2期440-454页
The potential impact of ankylosing spondylitis (AS) on cancer risk remains unclear. This study seeks to investigate the relationship between AS and different types of cancers.
9. Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: genome-wide meta-analysis and Mendelian randomization.
作者: Sizheng Steven Zhao.;Sarah L Mackie.;Susanna C Larsson.;Stephen Burgess.;Shuai Yuan.
来源: Rheumatology (Oxford). 2025年64卷5期3012-3018页
PMR is an age-related inflammatory disease of unknown cause. We aimed to identify potentially modifiable risk factors and therapeutic targets for preventing or treating PMR.
10. Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials.
作者: Berkay Kilic.;Admir Ozturk.;Sejla Karup.;Ervanur Hacioglu.;Serdal Ugurlu.
来源: Rheumatology (Oxford). 2025年64卷1期22-31页
Still's disease is a rare autoinflammatory disorder characterized by systemic inflammation, fever, rash and arthritis. The term 'Still's disease' covers the paediatric subtype systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), which affects adults. Biologic drugs, including the anti-IL-1 agents anakinra, canakinumab and rilonacept and the IL-6 antagonist tocilizumab, are used in the management of Still's disease.
11. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
作者: Eline J Arends.;Mihaela Zlei.;Christopher M Tipton.;Jasna Cotic.;Zgjim Osmani.;Fenna J de Bie.;Sylvia W A Kamerling.;Andre van Maurik.;Richard Dimelow.;Yun Irene Gregan.;Norma Lynn Fox.;Ton J Rabelink.;David A Roth.;Ignacio Sanz.;Jacques J M van Dongen.;Cees van Kooten.;Y K Onno Teng.
来源: Rheumatology (Oxford). 2024年63卷9期2387-2398页
Autoreactive memory B cells (MBCs) contribute to chronic and progressive courses in autoimmune diseases like SLE. The efficacy of belimumab (BEL), the first approved biologic treatment for SLE and LN, is generally attributed to depletion of activated naïve B cells and inhibition of B-cell activation. BEL's effect on MBCs is currently unexplained. We performed an in-depth cellular and transcriptomic analysis of BEL's impact on the blood MBC compartment in patients with SLE.
12. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study.
作者: Gonzalo Borrego-Yaniz.;Lourdes Ortiz-Fernández.;Adela Madrid-Paredes.;Martin Kerick.;José Hernández-Rodríguez.;Sarah L Mackie.;Augusto Vaglio.;Santos Castañeda.;Roser Solans.;Jaume Mestre-Torres.;Nader Khalidi.;Carol A Langford.;Steven Ytterberg.;Lorenzo Beretta.;Marcello Govoni.;Giacomo Emmi.;Marco A Cimmino.;Torsten Witte.;Thomas Neumann.;Julia Holle.;Verena Schönau.;Gregory Pugnet.;Thomas Papo.;Julien Haroche.;Alfred Mahr.;Luc Mouthon.;Øyvind Molberg.;Andreas P Diamantopoulos.;Alexandre Voskuyl.;Thomas Daikeler.;Christoph T Berger.;Eamonn S Molloy.;Daniel Blockmans.;Yannick van Sleen.;Mark Iles.;Louise Sorensen.;Raashid Luqmani.;Gary Reynolds.;Marwan Bukhari.;Shweta Bhagat.;Norberto Ortego-Centeno.;Elisabeth Brouwer.;Peter Lamprecht.;Sebastian Klapa.;Carlo Salvarani.;Peter A Merkel.;María C Cid.;Miguel A González-Gay.;Ann W Morgan.;Javier Martin.;Ana Márquez.; .; .; .
来源: Lancet Rheumatol. 2024年6卷6期e374-e383页
Giant cell arteritis is an age-related vasculitis that mainly affects the aorta and its branches in individuals aged 50 years and older. Current options for diagnosis and treatment are scarce, highlighting the need to better understand its underlying pathogenesis. Genome-wide association studies (GWAS) have emerged as a powerful tool for unravelling the pathogenic mechanisms involved in complex diseases. We aimed to characterise the genetic basis of giant cell arteritis by performing the largest GWAS of this vasculitis to date and to assess the functional consequences and clinical implications of identified risk loci.
13. Mental health conditions in patients with systemic lupus erythematosus: a systematic review and meta-analysis.
作者: Xiaotong Liu.;Xinlei Jia.;Xiao Wang.;Ya Bin Wei.;Jia Jia Liu.
来源: Rheumatology (Oxford). 2024年63卷12期3234-3242页
The reported prevalence of mental health conditions (MHCs) in people with systemic lupus erythematosus (SLE) ranges widely. Whether MHCs are associated with increased risk of SLE or the outcomes of the disease is unclear. This study aimed to conduct an umbrella and updated meta-analysis of MHCs in people with SLE and to identify whether MHCs are associated with the risk of SLE or patient outcomes.
14. Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis.
作者: Ivet Etchegaray-Morales.;Claudia Mendoza-Pinto.;Pamela Munguía-Realpozo.;Juan Carlos Solis-Poblano.;Socorro Méndez-Martínez.;Jorge Ayón-Aguilar.;Carlos Abud-Mendoza.;Mario García-Carrasco.;Ricard Cervera.
来源: Rheumatology (Oxford). 2024年63卷8期2047-2055页
To investigate the risk of DM and evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE.
15. Pharmacological interventions for early-stage frozen shoulder: a systematic review and network meta-analysis.
作者: Juan Enrique Berner.;Marios Nicolaides.;Stephen Ali.;Georgios Pafitanis.;Jane Preece.;Sally Hopewell.;Jagdeep Nanchahal.
来源: Rheumatology (Oxford). 2024年63卷12期3221-3233页
To evaluate the efficacy of pharmacological interventions for treating early-stage, pain predominant, adhesive capsulitis, also known as frozen shoulder.
16. The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis.
作者: Stephanie Lembke.;Gary J Macfarlane.;Gareth T Jones.
来源: Rheumatology (Oxford). 2024年63卷12期3211-3220页
Previous attempts to pool prevalence studies in PsA have failed to take account of important methodological differences between studies that may have created biased estimates. The aim of this review is to estimate the prevalence of PsA within the adult general population worldwide, considering potential differences between population-based and health administrative studies separately.
17. Risk of cardiovascular disease decreases over time in psoriatic arthritis but not in spondylarthritis: meta-analysis of longitudinal studies.
作者: Hélène Gouze.;Philippe Aegerter.;Yasmine Gouyette.;Maxime Breban.;Maria Antonietta D'Agostino.
来源: Rheumatology (Oxford). 2024年63卷10期2638-2647页
SpA and PsA represent two frequent inflammatory rheumatic disorders characterized by an increased burden on quality of life due to the association of several comorbidities, especially cardiovascular disease (CVD). The estimated prevalence of CVD ranges from 12 to 19% and differs between the two diseases, however, the incidence of CVD is not completely known. We aimed to systematically review the literature and perform a meta-analysis of controlled observational studies to assess the incidence rate of CVD over time in SpA and PsA.
18. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials.
作者: Kaoru Takase-Minegishi.;Stefan Böhringer.;Jackie L Nam.;Yuko Kaneko.;Frank Behrens.;Saedis Saevarsdottir.;Jacqueline Detert.;Marjatta Leirisalo-Repo.;Désirée van der Heijde.;Robert Landewé.;Sofia Ramiro.;Diane van der Woude.
来源: Rheumatology (Oxford). 2025年64卷2期548-560页
To investigate the efficacy of bDMARDs in patients with RA with RF/ACPA compared with patients without these autoantibodies.
19. Effect of gender and age on bDMARD efficacy for axial spondyloarthritis patients: a meta-analysis of randomized controlled trials.
To study the therapeutic variations of biologic and targeted synthetic DMARDs (b/tsDMARDs) between genders and across age stages in axial SpA (axSpA) patients through meta-analysis.
20. Identification of the VLDLR locus associated with giant cell arteritis and the possible causal role of low-density lipoprotein cholesterol in its pathogenesis.
作者: Takeshi Iwasaki.;Ryu Watanabe.;Hui Zhang.;Motomu Hashimoto.;Akio Morinobu.;Fumihiko Matsuda.
来源: Rheumatology (Oxford). 2024年63卷10期2754-2762页
To elucidate the association between genetic variants and the risk of GCA via large-scale genome-wide association studies (GWAS). In addition, to assess the causal effect of a specific molecule by employing the obtained GWAS results as genetic epidemiological tools.
|